:strip_icc()/s03.video.glbimg.com/x720/9079694.jpg)
[ad_1]
The American pharmaceutical company Pfizer sent this Sunday (6) a detailed document for health professionals in the United Kingdom with information about its vaccine against Covid-19. The document states that the immunizer should not be applied to pregnant or lactating women.
On Wednesday (2), the UK became the first country to announce the approval of the Pfzer / BioNtech vaccine. At that time, the English government also announced that plan to start vaccination next week. The NHS, the British public health service, will make a first batch of 10 million doses available in 2020.
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) said, in a note in the statement released Wednesday, that the approval of the vaccine was based on a “continuous review” of available data that began in October.
The Pfizer vaccine, developed in partnership with the BioNTech company, is one of four that are being tested in Brazil. The country has not yet reached an agreement to acquire the vaccine, but in mid-November, the government received executives from Pfizer to, according to the Ministry of Health, “to know the results of the ongoing tests and the conditions of purchase, logistics and warehousing offered “. by the laboratory. ”
In an interview with News, the director of the Brazilian Society of Immunizations (SBIm), Renato Kfouri, celebrated the approval of the vaccine in the United Kingdom – and said that is a milestone in the history of vaccine development. This is because the vaccine is the first of its kind to enter the market.
On Tuesday (1st), Pfizer applied for authorization to use its Covid-19 vaccine in Europe. The decision expires on December 29.
VIDEO: Pfizer vaccine approved in the UK and immunization begins next week
Vaccination status around the world:
- The UK was the first to approve the use of the Pfizer / BioNtech vaccine; vaccination is expected to begin next week;
- In November, Pfizer and Moderna submitted an application for authorization of their vaccines to the European Medicines Agency;
- Brazil has not yet approved the use of vaccines against Covid-19, but Anvisa has launched measures that can speed up the registration of immunizers in the country, such as the continuous sending of data;
- On Tuesday (1st), the Ministry of Health said that the Brazilian immunization plan does not foresee the use of vaccines that require extremely low storage temperatures;
- Portugal approved on Thursday a vaccination plan against Covid-19 (3); there, vaccination will be free and voluntary;
- In France, vaccination will be free and voluntary for all and should start in January for the elderly in nursing homes;
- In Moscow, Russia, vaccination will begin on Saturday; Russia was the first in the world to approve a Covid-19 vaccine in August, Sputnik V. In October, the country approved its second vaccine;
- In Japan, a bill approved on Wednesday (2) establishes that vaccination will be free
In Brazil, the National Health Surveillance Agency (Anvisa) approved measures that can speed up the registration of vaccines against Covid-19 in Brazil. One of these measures was the possibility of “continuous submission” of vaccine data by companies for evaluation by the agency.
In early November, the American pharmaceutical company announced that its candidate vaccine is 95% effective in preventing Covid-19, according to initial data from the third and final testing phase of the study. The data has not yet been published in a scientific journal.
In practice, if a vaccine is 95% effective, it means that 95% of the people who receive the vaccine are protected against this disease.
Pfizer said it plans to produce up to 50 million doses of vaccines in 2020 worldwide and 1.3 billion doses by the end of 2021. In July, the United States closed a deal with laboratories to purchase 100 million doses. this year, for US $ 1.95 billion (around R $ 10.1 billion).
